Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
Open accessThe DOI matches its Crossref record; 287 of the 288 references it cites were found in a registry or an index.
Abstract
Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung cancer. Irinotecan therapy is characterized by several dose-limiting toxicities and large interindividual pharmacokinetic variability. Irinotecan has a highly complex metabolism, including hydrolyzation by carboxylesterases to its active metabolite SN-38, which is 100- to 1000-fold more active compared with irinotecan itself. Several phase I and II enzymes, including cytochrome P450 (CYP) 3A4 and uridine diphosphate glucuronosyltransferase (UGT) 1A, are involved in the formation of inactive metabolites, making its metabolism prone to environmental and genetic influences. Genetic variants in the DNA of these enzymes and transporters could predict a part of the drug-related toxicity and efficacy of treatment, which has been shown in retrospective and prospective trials and meta-analyses. Patient characteristics, lifestyle and comedication also influence irinotecan pharmacokinetics. Other factors, including dietary restriction, are currently being studied. Meanwhile, a more tailored approach to prevent excessive toxicity and optimize efficacy is warranted. This review provides an updated overview on today's literature on irinotecan pharmacokinetics, pharmacodynamics, and pharmacogenetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Irinotecan or its activated form SN38 can be metabolically inactivated by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), cytochrome P450-3A4 (CYP3A4) and β-glucuronidase [104].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 2×
“The majority of the genetic association studies have focused on neutropenia and diarrhea as clinical endpoints [169].”
BackgroundIrinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Bosma, P. J., Chowdhury, J. R., Bakker, C., Gantla, S., de Boer, A., Oostra, B. A., Lindhout, D., Tytgat, G. N. J., Jansen, P. L. M., Elferink, R. P. J. O., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511023331802 · Cited by 1,447 · cited 1×
“Wild-type UGT1A1 is characterized by six thymine adenine (TA) repeats in the promotor region, whereas UGT1A1*28 (rs8175347) carriers have an extra TA repeat that impairs UGT1A1 transcription and thereby reduces expression by approximately 70% [234].”
BackgroundVan Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
Elad, S., Cheng, K. K. F., Lalla, R. V., Yarom, N., Hong, C., Logan, R. M., Bowen, J., Gibson, R., Saunders, D. P., Zadik, Y., et al. (2020) · Cancer · doi:10.1002/cncr.33100 · Cited by 1,336
Chemotherapy for advanced gastric cancer
Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,299
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259 · cited 2×
“As second-line treatment after 5-fluorouracil- containing regimens, irinotecan leads to a significantly longer OS than 5-fluorouracil with leucovorin or best supportive care (BSC) [166, 167].”
BackgroundFalcone, A., Ricci, S., Brunetti, I., Pfanner, E., Allegrini, G., Barbara, C., Crinò, L., Benedetti, G., Evangelista, W., Fanchini, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0928 · Cited by 1,241 · cited 1×
“FOLFOXIRI) substantially increased treatment efficacy, as shown by an RR of 60% and median OS of approximately 23 months [204, 205].”
BackgroundMASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
Lalla, R. V., Bowen, J., Barasch, A., Elting, L., Epstein, J., Keefe, D. M., McGuire, D. B., Migliorati, C., Nicolatou‐Galitis, O., Peterson, D. E., et al. (2014) · Cancer · doi:10.1002/cncr.28592 · Cited by 1,110
Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092
Richardson, M. A., Sanders, T., Palmer, J. L., Greisinger, A., & Singletary, S. E. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.13.2505 · Cited by 1,022 · cited 1×
“In general, herbal and dietary supplements are frequently used by cancer patients [155, 156].”
BackgroundPharmacogenetics: From Bench to Byte— An Update of Guidelines
Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A. H., Mulder, H., Rongen, G. A. P. J. M., van Schaik, R. H. N., Schalekamp, T., Touw, D. J., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.34 · Cited by 1,018
Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6055 · Cited by 1,005
Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03085-2 · Cited by 992 · cited 2×
“As second-line treatment after 5-fluorouracil- containing regimens, irinotecan leads to a significantly longer OS than 5-fluorouracil with leucovorin or best supportive care (BSC) [166, 167].”
BackgroundInnocenti, F., Undevia, S. D., Iyer, L., Xian Chen, P., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramírez, J., Rudin, C. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.173 · Cited by 964
Tabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D. C., Van Cutsem, E., Grothey, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70127-0 · Cited by 952
Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausova, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1193 · Cited by 946
Beutler, E., Gelbart, T., & Demina, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8170 · Cited by 853 · cited 2×
“The incidence of this genetic variant is relatively high among Caucasians (minor allele frequency [MAF] 26–39%) and Africans/ African Americans (MAF 30–56%) [235, 236].”
BackgroundHsiang, Y. H., & Liu, L. F. (1988) · PubMed · Cited by 841
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Self-citationBostwick, D. G., Pacelli, A., Blute, M., Roche, P., & Murphy, G. P. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980601)82:11<2256::aid-cncr22>3.0.co;2-s · Cited by 698
Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., & Ratain, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci915 · Cited by 686 · cited 1×
“UGT1A1 also conjugates bilirubin, and a significant correlation between SN-38 and bilirubin glucuronidation has been observed [42].”
BackgroundIntronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
Wang, D., Guo, Y., Wrighton, S. A., Cooke, G. E., & Sadee, W. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.28 · Cited by 505
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., & Ratain, M. J. (1994) · PubMed · Cited by 501
Circadian Timing in Cancer Treatments
Lévi, F., Okyar, A., Dulong, S., Innominato, P. F., & Clairambault, J. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094626 · Cited by 476
Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents
Sparreboom, A., Cox, M. C., Acharya, M. R., & Figg, W. D. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.182 · Cited by 473 · cited 1×
“In general, herbal and dietary supplements are frequently used by cancer patients [155, 156].”
BackgroundUGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters
Hoskins, J. M., Goldberg, R. M., Qu, P., Ibrahim, J. G., & McLeod, H. L. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm115 · Cited by 469 · cited 1×
“and hematologic toxicities were only reported for irinotecan doses higher than 180 mg/m(2) [242].”
BackgroundA kinetic and Mechanistic Study of the Hydrolysis of Camptothecin and Some Analogues
Fassberg, J., & Stella, V. J. (1992) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600810718 · Cited by 464 · cited 1×
“Consequently, a pH-dependent equilibrium between these forms exists [5].”
BackgroundEffects of St. John's wort on irinotecan metabolism.
Mathijssen, R. H. J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1247 · Cited by 457 · cited 2×
“Concomitant use of SJW resulted in a 42% reduction of SN-38 AUC, primarily caused by CYP3A4 induction (Table 1) [158].”
BackgroundInfluentialSelf-citationSaltz, L. B., Niedzwiecki, D., Hollis, D., Goldberg, R. M., Hantel, A., Thomas, J. P., Fields, A. L. A., & Mayer, R. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.2144 · Cited by 449 · cited 1×
“the addition of irinotecan to 5-fluorouracil and leucovorin did not result in a survival benefit [208, 209].”
BackgroundThe Role of Human Carboxylesterases in Drug Metabolism: Have We Overlooked Their Importance?
Casey Laizure, S., Herring, V., Hu, Z., Witbrodt, K., & Parker, R. B. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1194 · Cited by 446 · cited 1×
“To our knowledge, no clinically relevant drug–drug interactions (DDIs) involving CES have been reported for irinotecan, although both inhibitors and inducers of CES have been described, which could potentially influence the rate of irinotecan conversion to SN-38 [39].”
BackgroundHertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakas, D. R., Gallagher, G., Mattern, M. R., Mong, S. M., Bartus, J. O., Johnson, R. K., & Kingsbury, W. D. (1989) · Journal of Medicinal Chemistry · doi:10.1021/jm00123a038 · Cited by 413 · cited 1×
“As only the lactone form has antitumor activity, a small change in pH could alter the pharmacokinetics and efficacy of irinotecan [6].”
BackgroundBertagnolli, M. M., Niedzwiecki, D., Compton, C. C., Hahn, H. P., Hall, M., Damas, B., Jewell, S. D., Mayer, R. J., Goldberg, R. M., Saltz, L. B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2071 · Cited by 364 · cited 1×
“Patients with tumors characterized by high microsatellite instability (MSI) have been suggested to respond better to irinotecanbased chemotherapy, [210, 211] but a recent meta-analysis failed to show any predictive value of MSI status in relation to treatment response [212].”
BackgroundIYER, L., HALL, D., DAS, S., MORTELL, M., RAMIREZ, J., KIM, S., DIRIENZO, A., & RATAIN, M. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70078-0 · Cited by 356 · cited 1×
“Both UGT1A1*6 and *28 polymorphisms result in an increased systemic exposure to irinotecan and SN-38 in patients homozygous for these variants, thereby increasing the risk of irinotecan-associated adverse events [239, 240].”
BackgroundCharacterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.
Humerickhouse, R. A., Lohrbach, K., Li, L., BOSRON, W. F., & Dolan, M. E. (2000) · PubMed · Cited by 353
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Rothenberg, M. L., Eckardt, J. R., Kuhn, J. G., Burris, H. A., Nelson, J., Hilsenbeck, S. G., Rodriguez, G. I., Thurman, A. M., Smith, L. S., Eckhardt, S. G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.4.1128 · Cited by 352 · cited 4×
“, 1996 [188] 48 125–150 mg/m(2) Q1W No Yes ND ND”
InfluentialGagné, J.-F., Montminy, V., Belanger, P., Journault, K., Gaucher, G., & Guillemette, C. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.608 · Cited by 346
Shao, R.-G. (1999) · The EMBO Journal · doi:10.1093/emboj/18.5.1397 · Cited by 344 · cited 1×
“Irinotecan is the prodrug for SN-38, which inhibits topoisomerase-I, an enzyme involved in DNA replication [1, 2].”
BackgroundDank, M., Zaluski, J., Barone, C., Valvere, V., Yalcin, S., Peschel, C., Wenczl, M., Goker, E., Cisar, L., Wang, K., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn166 · Cited by 343 · cited 1×
“For advanced esophageal or junction tumors, irinotecan has proven to be effective as monotherapy and when combined with cisplatin, mitomycin, capecitabine and oxaliplatin, 5-fluorouracil and leucovorin and docetaxel [213–219]; however, of these regimens, only irinotecan combined with 5-fluorouracil was evaluated in a…”
BackgroundBallesta, A., Innominato, P. F., Dallmann, R., Rand, D. A., & Lévi, F. A. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.013441 · Cited by 339
Takasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M., Nagai, E., Yokoi, T., & Kamataki, T. (1996) · PubMed · Cited by 336
Zelefsky, M. J., Cowen, D., Fuks, Z., Shike, M., Burman, C., Jackson, A., Venkatramen, E. S., & Leibel, S. A. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990601)85:11<2460::aid-cncr23>3.0.co;2-n · Cited by 336
The structural basis of camptothecin interactions with human serum albumin: impact on drug stability
Burke, T. G., & Mi, Z. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00027a005 · Cited by 331 · cited 1×
“In plasma, the majority of irinotecan and SN-38 is bound to albumin, which has a stronger binding capacity for the more hydrophobic active metabolite, and albumin also stabilizes the lactone forms of irinotecan and SN-38 [10].”
BackgroundNozawa, T., Minami, H., Sugiura, S., Tsuji, A., & Tamai, I. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001909 · Cited by 316
Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines
Peterson, D. E., Bensadoun, R.-J., & Roila, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr391 · Cited by 305
Slatter, J. G., Schaaf, L. J., Sams, J. P., Feenstra, K. L., Johnson, M. G., Bombardt, P. A., Cathcart, K. S., Verburg, M. T., Pearson, L. K., Compton, L. D., et al. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15060-x · Cited by 302 · cited 4×
“%) and independent of dose, estimated at 12–21 L/h/m2 [59, 60].”
BackgroundInfluentialAbigerges, D., Chabot, G. G., Armand, J. P., Hérait, P., Gouyette, A., & Gandia, D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.210 · Cited by 299 · cited 3×
“…5–40 mg/m2 5D, continuously No Yesd ND ND de Forni et al., 1994 [186] 59 50–145 mg/m2 Q1W Yese Yese ND ND Rowinsky et al., 1994 [65] 32 100–345 mg/m2 Q3W No Yese ND ND Abigerges et al., 1995 [187] 64 100–750 mg/m2 Q3W Yesd Yesd ND ND Catimel et al., 1995 [67] 46 33–115 mg/m2 D1–D3, Q3W No No ND…”
InfluentialHan, J.-Y., Lim, H.-S., Shin, E. S., Yoo, Y.-K., Park, Y. H., Lee, J.-E., Jang, I.-J., Ho Lee, D., & Soo Lee, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0239 · Cited by 298
Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective
van Leeuwen, R. W. F., van Gelder, T., Mathijssen, R. H. J., & Jansman, F. G. A. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70579-5 · Cited by 279 · cited 1×
“Tyrosine kinase inhibitors (TKIs) have become very popular in cancer treatment but are also known for their modulating effects on drug-metabolizing enzymes [133].”
BackgroundSelf-citationXu, G. H., Zhang, W., Ma, M. K., & McLeod, H. L. (2002) · PubMed · Cited by 277
Strassburg, C. P., Oldhafer, K., Manns, M. P., & Tukey, R. H. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.2.212 · Cited by 275
Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal Cancer
Ilson, D. H., Saltz, L., Enzinger, P., Huang, Y., Kornblith, A., Gollub, M., O'Reilly, E., Schwartz, G., DeGroff, J., Gonzalez, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3270 · Cited by 268
Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics
Innocenti, F., Kroetz, D. L., Schuetz, E., Dolan, M. E., Ramírez, J., Relling, M., Chen, P., Das, S., Rosner, G. L., & Ratain, M. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6300 · Cited by 262 · cited 1×
“In addition, neutropenia appears to occur more frequently in females [174].”
BackgroundIrinotecan pathway genotype analysis to predict pharmacokinetics.
Mathijssen, R. H. J., Marsh, S., Karlsson, M. O., Xie, R., Baker, S. D., Verweij, J., Sparreboom, A., & McLeod, H. L. (2003) · PubMed · Cited by 258
Self-citationElens, L., Bouamar, R., Hesselink, D. A., Haufroid, V., van der Heiden, I. P., van Gelder, T., & van Schaik, R. H. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.165613 · Cited by 245
Mego, M., Chovanec, J., Vochyanova-Andrezalova, I., Konkolovsky, P., Mikulova, M., Reckova, M., Miskovska, V., Bystricky, B., Beniak, J., Medvecova, L., et al. (2015) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2015.03.008 · Cited by 236 · cited 1×
“Unfortunately, this did not result in a significant difference between groups, probably due to a lack of statistical power [195].”
BackgroundFallik, D., Borrini, F., Boige, V., Viguier, J., Jacob, S., Miquel, C., Sabourin, J., Ducreux, M. P., & Praz, F. (2003) · PubMed · Cited by 232
Rivory, L. P., Bowles, M. R., Robert, J., & Pond, S. M. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00457-1 · Cited by 228
McLeod, H. L., Sargent, D. J., Marsh, S., Green, E. M., King, C. R., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Thibodeau, S. N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.7943 · Cited by 216
Cecchin, E., Innocenti, F., D'Andrea, M., Corona, G., De Mattia, E., Biason, P., Buonadonna, A., & Toffoli, G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.0314 · Cited by 215
Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports
Wasserman, E., Myara, A., Lokiec, F., Goldwasser, F., Trivin, F., Mahjoubi, M., Misset, J. L., & Cvitkovic, E. (1997) · Annals of Oncology · doi:10.1023/a:1008261821434 · Cited by 213 · cited 1×
“in Gilbert’s syndrome, are at higher risk for severe toxicity when treated with irinotecan [48].”
BackgroundIdentification of a Defect in the UGT1A1 Gene Promoter and Its Association with Hyperbilirubinemia
Sugatani, J., Yamakawa, K., Yoshinari, K., Machida, T., Takagi, H., Mori, M., Kakizaki, S., Sueyoshi, T., Negishi, M., & Miwa, M. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6683 · Cited by 213 · cited 2×
“For instance, UGT1A1*60 (rs4124874; 3279T[G) is in linkage with UGT1A1*28 and is associated with a decrease in transcriptional activity [238].”
BackgroundMetabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
Santos, A., Zanetta, S., Cresteil, T., Deroussent, A., Pein, F. J. L., Raymond, É., Vernillet, L., Risse, M., Boige, V., Gouyette, A., et al. (2000) · PubMed · Cited by 213
Akaba, K., Kimura, T., Sasaki, A., Tanabe, S., Ikegami, T., Hashimoto, M., Umeda, H., Yoshida, H., Umetsu, K., Chiba, H., et al. (1998) · IUBMB Life · doi:10.1080/15216549800203512 · Cited by 207 · cited 1×
“With a reported MAF of up to 47%, another polymorphism—UGT1A1*6 (rs4148323, 211G[A)—is more common in Asian populations and may therefore be a better predictor for irinotecan-related toxicities in that area of the world [237].”
Backgroundde Jong, F. A., Marsh, S., Mathijssen, R. H. J., King, C., Verweij, J., Sparreboom, A., & McLeod, H. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0144 · Cited by 207
Self-citationYchou, M., Raoul, J.-L., Douillard, J.-Y., Gourgou-Bourgade, S., Bugat, R., Mineur, L., Viret, F., Becouarn, Y., Bouché, O., Gamelin, E., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn680 · Cited by 202 · cited 1×
“the addition of irinotecan to 5-fluorouracil and leucovorin did not result in a survival benefit [208, 209].”
BackgroundRowinsky, E. K., Grochow, L. B., Ettinger, D. S., Sartorius, S. E., Lubejko, B. G., Chen, T. L., Rock, M. K., & Donehower, R. C. (1994) · PubMed · Cited by 194
Taylor, R. R., Tang, Y., Gonzalez, M. V., Stratford, P. W., & Lewis, A. L. (2007) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.09.002 · Cited by 192
Nakatomi, K., Yoshikawa, M., Oka, M., Ikegami, Y., Hayasaka, S., Sano, K., Shiozawa, K., Kawabata, S., Soda, H., Ishikawa, T., et al. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5850 · Cited by 189
Masi, G., Vasile, E., Loupakis, F., Cupini, S., Fornaro, L., Baldi, G., Salvatore, L., Cremolini, C., Stasi, I., Brunetti, I., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq456 · Cited by 188 · cited 1×
“FOLFOXIRI) substantially increased treatment efficacy, as shown by an RR of 60% and median OS of approximately 23 months [204, 205].”
BackgroundGarufi, C., Torsello, A., Tumolo, S., Ettorre, G. M., Zeuli, M., Campanella, C., Vennarecci, G., Mottolese, M., Sperduti, I., & Cognetti, F. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605940 · Cited by 185
Gupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T. M., Vokes, E. E., & Ratain, M. J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1502 · Cited by 182 · cited 5×
“…mg/m2 Q1W No No No Yesb Abigerges et al., 1995 [187] 64 100–750 mg/m2 Q3W Yesc Yesc ND ND Catimel et al., 1995 [67] 46 33–115 mg/m2 D1–D3, Q3W Yesa No ND ND Gupta et al., 1997 [76] 40 145 mg/m2 Q1W No No No Yesb Canal et al., 1996 [68] 47 350 mg/m2 Q3W No No No No Mick et al., 1996 [183] 36 145…”
BackgroundResultInfluentialThe Role of β-Glucuronidase in Drug Disposition and Drug Targeting in Humans
Sperker, B., Backman, J. T., & Kroemer, H. K. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199733010-00003 · Cited by 177
Chabot, G. G., Abigerges, D., Catimel, G., Culine, S., de Forni, M., Extra, J.-M., Mahjoubi, M., Hérait, P., Armand, J.-P., Bugat, R., et al. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059109 · Cited by 173 · cited 2×
“Conversion by these esterases mainly occurs intrahepatically and is a relatively slow and inefficient process as only 2–5% of irinotecan is converted into SN-38 [12, 18].”
BackgroundIrinotecan-induced Diarrhea: Functional Significance of the Polymorphic ABCC2 Transporter Protein
de Jong, F. A., Scott-Horton, T. J., Kroetz, D. L., McLeod, H. L., Friberg, L. E., Mathijssen, R. H., Verweij, J., Marsh, S., & Sparreboom, A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100019 · Cited by 171
Self-citationToffoli, G., Cecchin, E., Gasparini, G., D'Andrea, M., Azzarello, G., Basso, U., Mini, E., Pessa, S., De Mattia, E., Lo Re, G., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6125 · Cited by 169
Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese
Sparreboom, A., Wolff, A. C., Mathijssen, R. H. J., Chatelut, E., Rowinsky, E. K., Verweij, J., & Baker, S. D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.2938 · Cited by 168 · cited 1×
“In addition, firm conclusions cannot be drawn for weight [13, 77].”
BackgroundSelf-citationBasch, E., Reeve, B., Cleeland, C., Sloan, J., Schrag, D., Atkinson, T., Mendoza, T., Hay, J., Abernethy, A., Minasian, L., et al. (2010) · Value in Health · doi:10.1016/s1098-3015(11)72017-4 · Cited by 163
Structural insights into CPT-11 activation by mammalian carboxylesterases
Bencharit, S., Morton, C. L., Howard-Williams, E. L., Danks, M. K., Potter, P. M., & Redinbo, M. R. (2002) · Nature Structural Biology · doi:10.1038/nsb790 · Cited by 161
Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups.
Innocenti, F., Grimsley, C., Das, S., Ramírez, J., Cheng, C., Kuttab-Boulos, H., Ratain, M. J., & Rienzo, A. D. (2002) · Pharmacogenetics · doi:10.1097/00008571-200212000-00006 · Cited by 159
Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice
Kawato, Y., Furuta, T., Aonuma, M., Yasuoka, M., Yokokura, T., & Matsumoto, K. (1991) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685508 · Cited by 159
Hanioka, N., Ozawa, S., Jinno, H., Ando, M., Saito, Y., & Sawada, J. (2001) · Xenobiotica · doi:10.1080/00498250110057341 · Cited by 158
Pozzo, C., Barone, C., Szántó, J., Pádi, É., Peschel, C., Bükki, J., Горбунова, В. А., Valvere, V., Załuski, J., Biakhov, M. Y., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh473 · Cited by 158
Liu, X., Cheng, D., Kuang, Q., Liu, G., & Xu, W. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.10 · Cited by 157 · cited 2×
“In another meta-analysis among Caucasian *28/*28 carriers, this dose-dependent effect was also observed [244].”
BackgroundMori, K., Kondo, T., Kamiyama, Y., Kano, Y., & Tominaga, K. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0585-0 · Cited by 157
Slatter, J. G., Su, P., Sams, J. P., Schaaf, L. J., & Wienkers, L. C. (1997) · PubMed · Cited by 152
Innocenti, F., Schilsky, R. L., Ramírez, J., Janisch, L. A., Undevia, S. D., House, L. K., Das, S., Wu, K., Turcich, M., Marsh, R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2307 · Cited by 152
Hall, D., Ybazeta, G., Destro‐Bisol, G., Petzl‐Erler, M. L., & Rienzo, A. D. (1999) · Pharmacogenetics and Genomics · doi:10.1097/00008571-199910000-00006 · Cited by 151 · cited 2×
“The incidence of this genetic variant is relatively high among Caucasians (minor allele frequency [MAF] 26–39%) and Africans/ African Americans (MAF 30–56%) [235, 236].”
BackgroundForni, M. D., Bugat, R., Chabot, G. G., Culine, S., Extra, J.-M., Gouyette, A., Madelaine, I., Marty, M. E., & Mathieu-Boué, A. (1994) · PubMed · Cited by 150
Saltz, L. B., Kanowitz, J., Kemeny, N. E., Schaaf, L. J., Spriggs, D. R., Staton, B. A., Berkery, R., Steger, C., Eng, M., Dietz, A. B., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.11.2959 · Cited by 145
Guichard, S. M., Terret, C., Hennebelle, I., Lochon, I., Chevreau, P., Frétigny, E., Sèlves, J., Chatelut, É., Bugat, R., & Canal, P. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690364 · Cited by 142
Ciotti, M., Basu, N. K., Brangi, M., & Owens, I. S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0453 · Cited by 141
Hu, Z., Yu, Q., Pei, Q., & Guo, C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1122 · Cited by 140 · cited 1×
“In addition, *28 carriers receiving lower irinotecan doses were at risk of neutropenia [243, 244].”
BackgroundElias, D. M., Matsuhisa, T., Sidéris, L., Liberale, G., Drouard-Troalen, L., Raynard, B., Pocard, M. D., Puizillou, J. M., Billard, V., Bourget, P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh398 · Cited by 136 · cited 1×
“A small fraction of irinotecan is rapidly converted intraperitoneally into SN38; systemic maximum concentration (Cmax) of SN-38 has been observed 30 min after intraperitoneal administration [98, 100].”
BackgroundRivory, L. P., Haaz, M., Canal, P., Lokiec, F. M., Armand, J., & Robert, J. (1997) · PubMed · Cited by 136
Wasserman, E., Cuvier, C., Lokiec, F. M., Goldwasser, F., Kalla, S., Méry-Mignard, D., Ould-Kaci, M., Besmaine, A., Dupont-André, G., Mahjoubi, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1751 · Cited by 134
Rivory, L. P., & Robert, J. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00689205 · Cited by 131 · cited 1×
“SN-38 is inactivated via glucuronidation to SN-38G by uridine diphosphate glucuronosyltransferase (UGT) and excreted into the bile [40, 41].”
BackgroundUGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan
Côté, J.-F., Kirzin, S., Kramar, A., Mosnier, J., Diébold, M.-D., Soubeyran, I., de Lajarte‐Thirouard, A., Sèlves, J., Laurent‐Puig, P., & Ychou, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2290 · Cited by 129
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.
van der Bol, J. M., Mathijssen, R. H. J., Loos, W. J., Friberg, L. E., van Schaik, R. H. N., de Jonge, M. J. A., Planting, A. S. T., Verweij, J., Sparreboom, A., & de Jong, F. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6115 · Cited by 128 · cited 2×
“Cigarette smoking resulted in a decrease in irinotecan and SN-38 exposure, possibly caused by CYP3A induction (Table 1) [162].”
BackgroundSelf-citationAminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion
Ishii, K., Usui, S., Sugimura, Y., Yoshida, S., Hioki, T., Tatematsu, M., Yamamoto, H., & Hirano, K. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(200102)9999:9999<::aid-ijc1178>3.0.co;2-6 · Cited by 128
Modulation of Irinotecan Metabolism by Ketoconazole
Kehrer, D. F. S., Mathijssen, R. H. J., Verweij, J., de Bruijn, P., & Sparreboom, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.177 · Cited by 124 · cited 1×
“The combination with the potent CYP3A4 inhibitor ketoconazole was one of the first significant DDIs described for irinotecan (Table 1) [142].”
BackgroundSelf-citationGlimelius, B. L. G., Garmo, H., Berglund, Å., Fredriksson, L. A., Berglund, M., Kohnke, H., Byström, P., Sørbye, H., & Wadelius, M. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.10 · Cited by 124
Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion
Ohe, Y., Sasaki, Y., Shinkai, T., Eguchi, K., Tamura, T., Kojima, A., Kunikane, H., Okamoto, H., Karato, A., Ohmatsu, H., et al. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.12.972 · Cited by 122 · cited 6×
“Two clinical studies did not report any significant associations between UGT1A1*60 status and Table 3 Overview of pharmacogenetic studies on irinotecan toxicity and survival Polymorphism Ethnicity Endpoint Dose range (mg/m2) Main findings No. of patients No. of studies References Meta-analyses UGT1A1*28/*28 (rs8175347…”
BackgroundInfluentialPharmGKB summary: very important pharmacogene information for UGT1A1
Barbarino, J. M., Haidar, C. E., Klein, T. E., & Altman, R. B. (2014) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000024 · Cited by 120 · cited 1×
“With more than 100 reported genetic variants [233], UGT1A1 is a highly polymorphic enzyme.”
BackgroundPrediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes
Mathijssen, R. H. J., de Jong, F. A., van Schaik, R. H. N., Lepper, E. R., Friberg, L. E., Rietveld, T., de Bruijn, P., Graveland, W. J., Figg, W. D., Verweij, J., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh298 · Cited by 119 · cited 1×
“The importance of CYP3A4 and CYP3A5 in irinotecan metabolism is underlined by the strong correlation between irinotecan and midazolam clearance [51].”
BackgroundSelf-citationClinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea
Xie, R., Mathijssen, R. H. J., Sparreboom, A., Verweij, J., & Karlsson, M. O. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.126741 · Cited by 116 · cited 3×
“…mg/m2 Q1W No Yesa ND ND Herben et al., 1999 [184] 29 10–12.5 mg/m2 D14–21, continuously No No No No de Jong et al., 2000 [66] 52 175–300 mg/m2 Q3W No No ND No Xie et al., 2002 [16] 109 100–350 mg/m2 Q3W Yes1 No Yesa No Neutropenia Ohe et al., 1992 [185] 36 5–40 mg/m2 5D, continuously No Yesd…”
ResultInfluentialSelf-citationIrinotecan (CPT-11) metabolism and disposition in cancer patients.
Sparreboom, A., de Jonge, M. J., de Bruijn, P., Brouwer, E., Nooter, K., Loos, W. J., van Alphen, R. J., Mathijssen, R. H. J., Stoter, G., & Verweij, J. (1998) · PubMed · Cited by 115
Self-citationUGT 1A1 genotype and irinotecan therapy: general review and implementation in routine practice
Étienne-Grimaldi, M.-C., Boyer, J.-C., Thomas, F., Quaranta, S., Picard, N., Loriot, M., Narjoz, C., Poncet, D., Gagnieu, M., Ged, C., et al. (2015) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12117 · Cited by 114
Dodds, H. M., Haaz, M., Riou, J., Robert, J., & Rivory, L. P. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37620-7 · Cited by 114 · cited 1×
“In contrast to APC, NPC can be converted to SN-38 by CES1 and CES2 in the liver, but to a lesser amount than irinotecan [50].”
BackgroundImpact of Body-Size Measures on Irinotecan Clearance: Alternative Dosing Recommendations
Mathijssen, R. H. J., Verweij, J., de Jonge, M. J. A., Nooter, K., Stoter, G., & Sparreboom, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.81 · Cited by 113 · cited 4×
“Additionally, increasing age may negatively influence irinotecan clearance, although this could not be confirmed in another analysis [13, 74].”
BackgroundInfluentialSelf-citationEffect of Milk Thistle (Silybum marianum) on the Pharmacokinetics of Irinotecan
van Erp, N. P. H., Baker, S. D., Zhao, M., Rudek, M. A., Guchelaar, H.-J., Nortier, J. W. R., Sparreboom, A., & Gelderblom, H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1288 · Cited by 113
Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN‐38
Paoluzzi, L., Singh, A. S., Price, D. K., Danesi, R., Mathijssen, R. H. J., Verweij, J., Figg, W. D., & Sparreboom, A. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004267159 · Cited by 113
Self-citationAtazanavir for the Treatment of Human Immunodeficiency Virus Infection
Busti, A. J., Hall, R. G., & Margolis, D. M. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.17.1732.52347 · Cited by 111 · cited 2×
“A similar effect could be expected of atazanavir, which is also a strong inhibitor of CYP3A4 and UGT1A1 [149].”
BackgroundCatimel, G., Chabot, G. G., Guastalla, J., Dumortier, A., Cote, C., Engel, C., Gouyette, A., Mathieu-Boué, A., Mahjoubi, M., & Clavel, M. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059108 · Cited by 111 · cited 2×
“…100–345 mg/m2 Q3W No No ND ND Gupta et al., 1994 [178] 21 100–175 mg/m2 Q1W No No No Yesb Abigerges et al., 1995 [187] 64 100–750 mg/m2 Q3W Yesc Yesc ND ND Catimel et al., 1995 [67] 46 33–115 mg/m2 D1–D3, Q3W Yesa No ND ND Gupta et al., 1997 [76] 40 145 mg/m2 Q1W No No No Yesb Canal et al., 1996…”
CPT-11-induced cholinergic effects in cancer patients.
Gandía, D., Abigerges, D., Armand, J., Chabot, G. G., Costa, L. M. D., Forni, M. D., Mathieu-Boué, A., & Herait, P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.1.196 · Cited by 108 · cited 1×
“Early-onset diarrhea starts during, or immediately after, drug infusion and is caused by increased cholinergic activity, which stimulates intestinal contractility and reduces the absorptive capacity of the mucosa [175].”
BackgroundCanal, P., Gay, C., Dezeuze, A., Douillard, J., Bugat, R., Brunet, R., Adenis, A., Herait, P., Lokiec, F. M., & Mathieu-Boué, A. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2688 · Cited by 108 · cited 5×
“been contradictory; a higher biliary index was significantly correlated with a higher incidence of severe diarrhea in several studies [76, 178, 183], whereas no significant association was found in other studies (see Table 2) [16, 66, 68, 184].”
BackgroundResultInfluentialHan, J., Lim, H., Park, Y. H., Lee, S., & Lee, J. S. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.12.003 · Cited by 107
Intestinal microflora and digestive toxicity of irinotecan in mice.
Brandi, G., Dabard, J., Raibaud, P., Di Battista, M., Bridonneau, C., Pisi, A. M., Morselli Labate, A. M., Pantaleo, M. A., De Vivo, A., & Biasco, G. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0750 · Cited by 106
Bodurka, D. C., Levenback, C., Wolf, J. K., Gano, J. B., Wharton, J. T., Kavanagh, J. J., & Gershenson, D. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.091 · Cited by 102
Clinical Pharmacokinetics of Irinotecan and Its Metabolites: A Population Analysis
Xie, R., Mathijssen, R. H. J., Sparreboom, A., Verweij, J., & Karlsson, M. O. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.073 · Cited by 101 · cited 5×
“…mg/m2 Q1W No Yesa ND ND Herben et al., 1999 [184] 29 10–12.5 mg/m2 D14–21, continuously No No No No de Jong et al., 2000 [66] 52 175–300 mg/m2 Q3W No No ND No Xie et al., 2002 [16] 109 100–350 mg/m2 Q3W Yes1 No Yesa No Neutropenia Ohe et al., 1992 [185] 36 5–40 mg/m2 5D, continuously No Yesd…”
BackgroundInfluentialSelf-citationRapid synthesis of transition-metal borides by solid-state metathesis
Rao, L., Gillan, E. G., & Kaner, R. B. (1995) · Journal of materials research/Pratt's guide to venture capital sources · doi:10.1557/jmr.1995.0353 · Cited by 100
Rivory, L. P., Chatelut, É., Canal, P., Mathieu-Boué, A., & Robert, J. (1994) · PubMed · Cited by 98
Clinically significant pharmacokinetic drug interactions between antiepileptic drugs
Tanaka, E. (1999) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1999.00201.x · Cited by 96 · cited 11×
“The prodrug irinotecan is hydrolyzed into the active metabolite SN-38 by two isoforms of carboxylesterases (CES1 and 2) and butyrylcholinesterase in the human body (Fig.”
BackgroundInfluentialDeterminants of CPT-11 and SN-38 activities in human lung cancer cells
van Ark-Otte, J., Kedde, M., van der Vijgh, W., Dingemans, A. C., Jansen, W., Pinedo, H. M., Boven, E., & Giaccone, G. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.362 · Cited by 96
Sugiyama, Y., Kato, Y., & Chu, X. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051078 · Cited by 95
Hu, Z., Yu, Q., & Zhao, Y. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.049 · Cited by 92
Morton, C. L., Wadkins, R. M., Danks, M. K., & Potter, P. M. (1999) · PubMed · Cited by 91
Kong, R., Liu, T., Zhu, X., Ahmad, S., Williams, A. L., Phan, A. T., Zhao, H., Scott, J. E., Yeh, L.-A., & Wong, S. T. C. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0395 · Cited by 90 · cited 1×
“In addition, b-glucuronidase activity has been correlated to intestinal damage and diarrhea in rats/mice, which could (potentially) be reduced by inhibiting b-glucuronidase with antibiotics (penicillin and streptomycin) or amopaxine [56, 57].”
BackgroundGuetz, G. D., Uzzan, B., Nicolas, P., Schischmanoff, P. O., Perret, G. Y., & Morère, J. (2009) · PubMed · Cited by 90
Chu, X., Kato, Y., Ueda, K., Suzuki, H., Niinuma, K., Tyson, C. A., Weizer, V., Dabbs, J. E., Froehlich, R., Green, C. E., et al. (1998) · PubMed · Cited by 90
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38
Singh, A. S., Paoluzzi, L., Price, D. K., Danesi, R., Mathijssen, R. H. J., Verweij, J., Figg, W. D., & Sparreboom, A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.2072 · Cited by 90
Self-citationde Jong, F. A., Kehrer, D. F. S., Mathijssen, R. H. J., Creemers, G.-J., de Bruijn, P., van Schaik, R. H. N., Planting, A. S. T., van der Gaast, A., Eskens, F. A. L. M., Janssen, J. T. P., et al. (2006) · The Oncologist · doi:10.1634/theoncologist.11-8-944 · Cited by 89 · cited 1×
“Nonetheless, attempts to reduce b-glucuronidase activity by neomycin did not significantly alter the irinotecan pharmacokinetic profile in patients [58].”
BackgroundSelf-citationCole, C. B., Fuller, R., Mallet, A. K., & Rowland, I. R. (1985) · Journal of Applied Bacteriology · doi:10.1111/j.1365-2672.1985.tb03359.x · Cited by 88
Rivory, L. P. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)02009-8 · Cited by 86 · cited 1×
“SN-38 is 100- to 1000-fold more cytotoxic than irinotecan, and its exposure is highly variable [3].”
BackgroundComparative Analysis of Esterase Activities of Human, Mouse, and Rat Blood
Рудакова, Е. В., Boltneva, N. P., & Махаева, Г. Ф. (2011) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-011-1457-y · Cited by 85 · cited 12×
“The prodrug irinotecan is hydrolyzed into the active metabolite SN-38 by two isoforms of carboxylesterases (CES1 and 2) and butyrylcholinesterase in the human body (Fig.”
BackgroundInfluentialCheng, L., Li, M., Hu, J. Y., Ren, W., Xie, L., Sun, Z., Liu, B., Xu, G., Dong, X., & Qian, X. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2382-3 · Cited by 84 · cited 2×
“This association does not seem to be dose-dependent [248].”
BackgroundVanhoefer, U., Harstrick, A., Köhne, C.-H., Achterrath, W., Rustum, Y. M., Seeber, S., & Wilke, H. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.907 · Cited by 83
Klein, C. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.129502 · Cited by 83 · cited 6×
“A mean SN-38 distribution half-life was estimated to be very short (approximately 8 min) [13].”
BackgroundInfluentialRea, D., Nortier, J. W. R., Huinink, W. W. T. B., Falk, S. J., Richel, D. J., Maughan, T., Groenewegen, G., Smit, J. M., Steven, N. M., Bakker, J. M., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi227 · Cited by 81
Diekstra, M. H. M., Klümpen, H., Lolkema, M. P., Yu, H., Kloth, J. S. L., Gelderblom, H. A. J., van Schaik, R. H. N., Gurney, H., Swen, J. J., Huitema, A. D. R., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.47 · Cited by 80
Self-citationCaraci, F., Crupi, R., Drago, F., & Spina, E. (2011) · Current Drug Metabolism · doi:10.2174/138920011795713706 · Cited by 80 · cited 1×
“Hypothetically, other strong CYP3A4-inhibiting antidepressants such as nefazodone could be suspected for an interaction with irinotecan [144].”
BackgroundPhase II Study of Activated Charcoal to Prevent Irinotecan-Induced Diarrhea
Michael, M., Brittain, M., Nagai, J., Feld, R., Hedley, D., Oza, A., Siu, L., & Moore, M. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.125 · Cited by 79 · cited 1×
“Until now, only the activated charcoal has been found to reduce the incidence of diarrhea [191, 192]; however, evidence from a phase III study and additional pharmacokinetic analysis is warranted to understand the real effect of activated charcoal, which also exhibits a general antidiarrhoeic effect, and therefore the…”
BackgroundTeft, W. A., Welch, S. A., Lenehan, J. G., Parfitt, J. R., Choi, Y.-H., Winquist, E., & Kim, R. B. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.5 · Cited by 77
Lenfers, B., Loeffler, T. M., Droege, C., & Hausamen, T.-U. (1999) · Annals of Oncology · doi:10.1023/a:1008390308416 · Cited by 76
Martin, R. C. G., Scoggins, C. R., Tomalty, D., Schreeder, M. T., Metzger, T. L., Tatum, C. M., & Sharma, V. R. (2012) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-012-1892-8 · Cited by 76
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Lamb, Y. N., & Scott, L. J. (2017) · Drugs · doi:10.1007/s40265-017-0741-1 · Cited by 76 · cited 1×
“Liposomal irinotecan has recently been approved as second-line treatment for metastatic pancreatic cancer for patients with progression on gemcitabine-based therapies [87].”
BackgroundMedicinal Cannabis Does Not Influence the Clinical Pharmacokinetics of Irinotecan and Docetaxel
Engels, F. K., de Jong, F. A., Sparreboom, A., Mathot, R. A. A., Loos, W. J., Kitzen, J. J. E. M., de Bruijn, P., Verweij, J., & Mathijssen, R. H. J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-3-291 · Cited by 74 · cited 1×
“medicinal cannabis tea [163], other cannabis formulations contain different concentrations of the enzyme-modulating compounds (e.”
BackgroundSelf-citationA CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan
van der Bol, J. M., Mathijssen, R. H. J., Creemers, G., Planting, A. S. T., Loos, W. J., Wiemer, E. A. C., Friberg, L. E., Verweij, J., Sparreboom, A., & de Jong, F. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1526 · Cited by 73 · cited 1×
“By dosing on this algorithm, the interindividual variability in irinotecan and SN-38 exposure dramatically reduced compared with conventional dosing [52].”
BackgroundSelf-citationSugiyama, T., Nishida, T., Kumagai, S., Nishio, S., Fujiyoshi, K., Okura, N., YAKUSHIJI, M., Hiura, M., & Umesaki, N. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690656 · Cited by 72
Haaz, M., Rivory, L. P., Riché, C., & Robert, J. (1997) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00005049 · Cited by 70 · cited 1×
“This could be explained by a higher tissue distribution of irinotecan lactone and the preferential binding of SN-38 lactone to plasma proteins [4, 9].”
Backgroundvan Riel, J. M. G. H., van Groeningen, C. J., Kedde, M. A., Gall, H. E., Leisink, J. M. A., Gruia, G., Pinedo, H. M., van der Vijgh, W. J. F., & Giaccone, G. (2002) · PubMed · Cited by 69
Ohtsuka, K., Inoue, S., Kameyama, M., Kanetoshi, A., Fujimoto, T., Takaoka, K., Araya, Y., & SHIDA, A. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)00223-x · Cited by 69
Dulong, S., Ballesta, A., Okyar, A., & Lévi, F. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0129 · Cited by 68
Campbell, J. M., Stephenson, M., Bateman, E. H., Peters, M. D. J., Keefe, D. M. K., & Bowen, J. M. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.58 · Cited by 68 · cited 1×
“Whether this association is dose-dependent is currently unknown since no dose subgroup analysis has been carried out [250].”
BackgroundPhase II Study of Irinotecan Plus Cisplatin in Patients With Advanced Non–Small-Cell Lung Cancer
DeVore, R. F., Johnson, D. H., Crawford, J., Garst, J. L., Dimery, I. W., Eckardt, J. R., Eckhardt, S. G., Elfring, G. L., Schaaf, L. J., Hanover, C. K., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2710 · Cited by 67
Enzinger, P. C., Kulke, M. H., Clark, J. W., Ryan, D. P., Kim, H. T., Earle, C. C., Vincitore, M., Michelini, A. L., Mayer, R. J., & Fuchs, C. S. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-3038-2 · Cited by 66
Masuda, N., Fukuoka, M., Kudoh, S., Matsui, K., Kusunoki, Y., Takada, M., Nakagawa, K., Hirashima, T., Tsukada, H., & Yana, T. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.9.1833 · Cited by 66
Mick, R., Gupta, E., Vokes, E. E., & Ratain, M. J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2012 · Cited by 66 · cited 3×
“…1995 [67] 46 33–115 mg/m2 D1–D3, Q3W Yesa No ND ND Gupta et al., 1997 [76] 40 145 mg/m2 Q1W No No No Yesb Canal et al., 1996 [68] 47 350 mg/m2 Q3W No No No No Mick et al., 1996 [183] 36 145 mg/m2 Q1W ND ND ND Yesa Rothenberg et al., 1996 [188] 48 125–150 mg/m2 Q1W No Yesa ND ND Herben et al.,…”
ResultPoujol, S., Pinguet, F., Malosse, F., Astre, C., Ychou, M., Culine, S., & Bressolle, F. (2003) · Clinical Chemistry · doi:10.1373/clinchem.2003.023481 · Cited by 65
In Vitro Binding and Partitioning of Irinotecan (CPT-11) and its Metabolite, SN-38, in Human Blood
Combes, O., Barré, J., Duché, J.-C., Vernillet, L., Archimbaud, Y., Marietta, M. P., Tillement, J. P., & Urien, S. (2000) · Investigational New Drugs · doi:10.1023/a:1006379730137 · Cited by 63 · cited 2×
“The binding constant of SN-38 with erythrocytes is almost 15-fold higher than that of irinotecan [11].”
BackgroundWierdl, M., Morton, C. L., Weeks, J. K., Danks, M. K., Harris, L. C., & Potter, P. M. (2001) · PubMed · Cited by 63
Elias, D. M., Raynard, B., Bonnay, M., & Pocard, M. D. (2006) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2006.03.004 · Cited by 63
Glucuronidation of SN‐38, the Active Metabolite of Irinotecan, by Human Hepatic Microsomes
Haaz, M., Rivory, L. P., Jantet, S., Ratanasavanh, D., & Robert, J. (1997) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1997.tb00289.x · Cited by 63 · cited 1×
“SN-38 is inactivated via glucuronidation to SN-38G by uridine diphosphate glucuronosyltransferase (UGT) and excreted into the bile [40, 41].”
BackgroundLhommé, C., Fumoleau, P., Fargeot, P., Krakowski, Y., Dieras, V. C., Chauvergne, J., Vennin, P., Rebattu, P., Roché, H., Misset, J. L., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3136 · Cited by 61
Kehrer, D. F. S., Yamamoto, W., Verweij, J., de Jonge, M. J., de Bruijn, P., & Sparreboom, A. (2000) · PubMed · Cited by 60
Adjei, A. A., Klein, C. E., Kastrissios, H., Goldberg, R. M., Alberts, S. R., Pitot, H. C., Sloan, J. A., Reid, J. M., Hanson, L. J., Atherton, P. J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.1116 · Cited by 59
Lévesque, É., Bélanger, A.-S., Harvey, M., Couture, F., Jonker, D. J., Innocenti, F., Cecchin, E., Toffoli, G., & Guillemette, C. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.202242 · Cited by 59
de Jonge, M. J. A., Verweij, J., de Bruijn, P., Brouwer, E., Mathijssen, R. H. J., Alphen, R. J. V., de Boer-Dennert, M. M., Vernillet, L., Jacques, C. J., & Sparreboom, A. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.195 · Cited by 58 · cited 3×
“been contradictory; a higher biliary index was significantly correlated with a higher incidence of severe diarrhea in several studies [76, 178, 183], whereas no significant association was found in other studies (see Table 2) [16, 66, 68, 184].”
ResultSelf-citationHerben, V. M. M., Schellens, J. H. M., Swart, M., Gruia, G., Vernillet, L., Beijnen, J. H., & Huinink, W. W. T. B. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1897 · Cited by 58 · cited 3×
“…1995 [67] 46 33–115 mg/m2 D1–D3, Q3W No No ND ND Canal et al., 1996 [68] 47 350 mg/m2 Q3W Yese Yese No No Rothenberg et al., 1996 [188] 48 125–150 mg/m2 Q1W No No ND ND Herben et al., 1999 [184] 29 10–12.5 mg/m2 D14–21, continuously No No No No de Jong et al., 2000 [66] 52 175–300 mg/m2 Q3W No…”
ResultInfluentialSasaki, Y., Yoshida, Y., Sudoh, K., Hakusui, H., Fujii, H., Ohtsu, T., Wakita, H., Igarashi, T., & Itoh, K. (1995) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1995.tb02995.x · Cited by 58 · cited 3×
“Irinotecan is assumed to exhibit linear pharmacokinetics because of the correlation between dose and systemic exposure, which is highly variable between patients [8].”
BackgroundA phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital
INNOCENTI, F., UNDEVIA, S., RAMIREZ, J., MANI, S., SCHILSKY, R., VOGELZANG, N., PRADO, M., & RATAIN, M. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.07.016 · Cited by 57 · cited 9×
“Subsequently, phenobarbital (as a UGT1A1 inductor) was added, and the combination of cyclosporine/phenobarbital/irinotecan resulted in a 75% reduction of SN-38 AUC [147].”
BackgroundInfluentialSantoro, A., Comandone, A., Rimassa, L., Granetti, C., Lorusso, V., Oliva, C., Ronzoni, M., Siena, S., Zuradelli, M., Mari, E., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn401 · Cited by 57
Midgley, R. S., Kerr, R. S., Flaherty, K. T., Stevenson, J. P., Pratap, S., Koch, K. M., Smith, D. A., Versola, M., Fleming, R. A., Ward, C., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm366 · Cited by 56
Akinwande, O., Dendy, M., Ludwig, J. M., & Kim, H. S. (2017) · Surgical Oncology · doi:10.1016/j.suronc.2017.05.003 · Cited by 56 · cited 1×
“for unresectable liver metastases [86].”
Moehler, M. H., Kanzler, S., Geißler, M., Raedle, J., Ebert, M., Daum, S., Flieger, D., Seufferlein, T. T. W., Galle, P. R., & Hoehler, T. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp269 · Cited by 54
UGT1A1predicts outcome in colorectal cancer treated with irinotecan and fluorouracil
Wang, Y. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i45.6635 · Cited by 52 · cited 1×
“Both UGT1A1*6 and *28 polymorphisms result in an increased systemic exposure to irinotecan and SN-38 in patients homozygous for these variants, thereby increasing the risk of irinotecan-associated adverse events [239, 240].”
BackgroundFlat-Fixed Dosing of Irinotecan
de Jong, F. A., Mathijssen, R. H. J., Xie, R., Verweij, J., & Sparreboom, A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0591 · Cited by 52 · cited 1×
“Although irinotecan dose is generally based on BSA, it has been shown that BSA and other body size measures do not predict irinotecan pharmacokinetics, and that flat-fixed dosing could be a safe alternative [74, 78].”
BackgroundSelf-citationCorona, G., Vaccher, E., Sandron, S., Sartor, I., Tirelli, U., Innocenti, F., & Toffoli, G. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100330 · Cited by 51 · cited 2×
“In addition, an important DDI between irinotecan and the combination treatment with ritonavir and lopinavir, caused by CYP3A4, UGT1A1, and ABC transporter inhibition resulted in a more than twofold increase in SN-38 AUC and a 36% decrease in the SN-38G/SN-38 AUC ratio (Table 1) [148].”
BackgroundIrinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38
Mathijssen, R. H. J., Verweij, J., Loos, W. J., de Bruijn, P., Nooter, K., & Sparreboom, A. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600447 · Cited by 51 · cited 4×
“, 2002 [73] 26 350 mg/m(2) Q3W ND Yes ND ND”
BackgroundInfluentialSelf-citationVeronese, M. L., Sun, W., Giantonio, B. J., Berlin, J. D., Justine Shults, A., Davis, L. E., Haller, D. G., & O'Dwyer, P. J. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602569 · Cited by 51
Advances in pharmacotherapy of small cell lung cancer
Kalemkerian, G. P. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.957180 · Cited by 51 · cited 1×
“For advanced SCLC, irinotecan combined with cisplatin or carboplatin had similar RR and median OS as platinum compounds with etoposide (RR 39–84% and median OS 9–13 months) and is therefore used as first-line treatment in Japan, whereas the etoposide-containing regimen is preferred elsewhere [223].”
MethodABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia
Li, M., Seiser, E. L., Baldwin, R. M., Ramirez, J., Ratain, M. J., Innocenti, F., & Kroetz, D. L. (2018) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.75 · Cited by 50
Karthaus, M., Ballo, H., Abenhardt, W., Steinmetz, T., Geer, T., Schimke, J., Braumann, D., Behrens, R., Behringer, D., Kindler, M., et al. (2005) · Oncology · doi:10.1159/000086971 · Cited by 49
Johnson, F. M., Krug, L. M., Tran, H. T., Shoaf, S., Prieto, V. G., Tamboli, P., Peeples, B. O., Patel, J. D., & Glisson, B. S. (2005) · Cancer · doi:10.1002/cncr.21640 · Cited by 48 · cited 1×
“D1? 8, Q3W Irinotecan AUC8 67% :, CL 36% ; [134]”
Lin, L.-C., Wang, M.-N., & Tsai, T. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2008.05.033 · Cited by 48
Irinotecan and temozolomide brain distribution: a focus on ABCB1
Goldwirt, L., Beccaria, K., Carpentier, A. C., Farinotti, R., & Fernandez, C. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2490-0 · Cited by 48 · cited 1×
“irinotecan concentrations in mice [64].”
Han, F., Guo, C., Yu, D., Zhu, J., Gong, L., Li, G., Lv, Y., He, L., An, G., & Liu, L. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2405-0 · Cited by 47 · cited 1×
“In contrast, UGT1A1*6 seems to be a more accurate predictor of irinotecan-induced toxicity; Asian patients with gastrointestinal tumors or NSCLC were more likely to suffer from neutropenia if they were carrying at least one UGT1A1*6 allele (Table 3) [245, 247].”
BackgroundInfluence of bile salts on β-glucuronidase activity of intestinal bacteria
Fujisawa, T., & Mori, M. (1996) · Letters in Applied Microbiology · doi:10.1111/j.1472-765x.1996.tb01159.x · Cited by 47
Chen, S., Villeneuve, L., Jonker, D. J., Couture, F., Laverdière, I., Cecchin, E., Innocenti, F., Toffoli, G., Lévesque, É., & Guillemette, C. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000168 · Cited by 46
Flieger, D., Klassert, C., Hainke, S., Keller, R., Kleinschmidt, R., & Fischbach, W. (2007) · Oncology · doi:10.1159/000111083 · Cited by 45
Gholam, D., Giacchetti, S., Brézault, C., Bouchahda, M., Hauteville, D., Adam, R. A., Ducot, B., Ghémard, O., Kustlinger, F., Jasmin, C., et al. (2006) · The Oncologist · doi:10.1634/theoncologist.11-10-1072 · Cited by 45
Basel, M. T., Balivada, S., Shrestha, T. B., Seo, G., Pyle, M. M., Tamura, M., Bossmann, S. H., & Troyer, D. L. (2012) · Small · doi:10.1002/smll.201101879 · Cited by 45
CPT-11 (Irinotecan) and 5-Fluorouracil: a Promising Combination for Therapy of Colorectal Cancer
Saltz, L. B., Shimada, Y., & Khayat, D. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00294-8 · Cited by 45
Toffoli, G., Sharma, M. R., Marangon, E., Posocco, B., Gray, E., Mai, Q., Buonadonna, A., Polite, B. N., Miolo, G., Tabaro, G., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1012 · Cited by 44
Javle, M. M., Cao, S., Durrani, F. A., Pendyala, L., Lawrence, D. D., Smith, P. F., Creaven, P. J., Noel, D., Iyer, R. V., & Rustum, Y. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0551 · Cited by 43 · cited 1×
“Studies that did not show a significant drug–drug interaction [131, 132, 152, 153] are illustrated in more detail in the text 1234 F.”
BackgroundEffects of Green Tea Compounds on Irinotecan Metabolism
Mirkov, S., Komoroski, B. J., Ramírez, J., Graber, A. Y., Ratain, M. J., Strom, S. C., & Innocenti, F. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012047 · Cited by 43 · cited 1×
“Flavonoids are components of many herbs, such as milk thistle (Silybum marianum), and are able to inhibit CYP3A4, UGT1A1 and ABC transporters [159–161], but an interaction has not yet been demonstrated in clinical trials [161].”
BackgroundHuisman, S. A., Bijman-Lagcher, W., IJzermans, J. N., Smits, R., & de Bruin, R. W. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1044170 · Cited by 42 · cited 1×
“Systemic and hepatic exposure to SN-38 was reduced in these mice, but intratumoral concentrations were unaltered [202, 203].”
Background
Research works printed but not linked: 2
- National Institutes of Health Common terminology criteria for adverse events (CTCAE) 2010 Bethesda National Institutes of Health
- Murphy BA Cmelak A Burkey B Netterville J Shyr Y Douglas S Topoisomerase I inhibitors in the treatment of head and neck cancer Oncology (Williston Park) 2001 15 7 Suppl 8 47 52 11497232
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Drug resistance and new therapies in colorectal cancer
Jeught, K. V. D., Xu, H.-C., Li, Y.-J., Lu, X.-B., & Ji, G. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i34.3834 · Cited by 597
Wainberg, Z. A., Melisi, D., Macarulla, T., Pazo Cid, R., Chandana, S. R., De La Fouchardière, C., Dean, A., Kiss, I., Lee, W. J., Goetze, T. O., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01366-1 · Cited by 516
Irinotecan: 25 years of cancer treatment
Bailly, C. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104398 · Cited by 456
Hwang, W. L., Jagadeesh, K. A., Guo, J. A., Hoffman, H. I., Yadollahpour, P., Reeves, J. W., Mohan, R., Drokhlyansky, E., Van Wittenberghe, N., Ashenberg, O., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01134-8 · Cited by 426
Metadata
- Authors
- de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S.
- Affiliations
- Erasmus MC (NL)
- Erasmus MC Cancer Institute (NL)
- Corresponding author
- Bins, Sander
- Venue
- Clinical Pharmacokinetics
- Published
- 2018-03-08
- Volume
- 57
- Issue
- 10
- Pages
- 1229-1254
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- PMC
- PMC6132501
- OpenAlex
- W2790768119
- Cited by
- 421
- References
- 288
- Citations by year
- 2026: 41 · 2025: 51 · 2024: 58 · 2023: 69 · 2022: 63 · 2021: 67 · 2020: 41 · 2019: 22 · 2018: 8
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- Locations
- Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- irinotecan, pharmacokinetics, pharmacodynamics, pharmacogenetics, SN-38, carboxylesterase, CYP3A4, UGT1A, topoisomerase I inhibitor, dose-limiting toxicity, interindividual variability, drug metabolism, genetic variants
- MeSH terms
- Irinotecan, UGT1A1 Enzyme, Drug Interactions, Humans, Inactivation, Metabolic, Tissue Distribution, Glucuronosyltransferase, Area Under Curve, Polymorphism, Single Nucleotide, Cytochrome P-450 CYP3A, Precision Medicine, Topoisomerase I Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.